IDIOPATHIC PULMONARY FIBROSIS

This phase 2 trial tests an oral drug called PIPE-791 in 324 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Participants take either a low or high dose of PIPE-791 or a placebo daily for several months. The main goal is t…

This study tests a drug called H01 (hymecromone) in adults with interstitial lung disease, a condition that causes lung scarring and makes breathing hard. The goal is to see if H01 can lower a marker of lung damage and improve lung function. Participants take the drug as a tablet…

This study tests the long-term safety of the drug nerandomilast in people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). All 1,700 participants have already taken the drug in a previous study. They will take nerandomilast tablets for up to 1 yea…

This study tests a new medicine called BI 765423 in 71 adults with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing problems. Participants receive either the drug or a placebo by infusion every four weeks for about 3 months. The main goal is …

This phase 2 trial tests whether MTX-463, an antibody that blocks a protein linked to scarring, can slow lung function decline in people with idiopathic pulmonary fibrosis (IPF). About 164 adults with IPF will receive either the drug or a placebo for 24 weeks. The main goal is to…

This study tests whether adding the antibiotic azithromycin to standard treatment helps people with idiopathic pulmonary fibrosis (IPF) recover faster from sudden, severe flare-ups. Researchers will compare hospital stay length and other outcomes between those who get azithromyci…

This study tests whether the drug senicapoc can prevent lung scarring from getting worse in people with progressive fibrotic interstitial lung disease (ILD) or idiopathic pulmonary fibrosis (IPF). About 140 adults will take either senicapoc or a placebo daily for 26 weeks, and do…

This study tests an experimental drug called ABBV-142 in people with idiopathic pulmonary fibrosis (IPF), a rare lung disease that causes scarring and breathing problems. About 165 adults will receive either ABBV-142 or a placebo for 52 weeks to see if the drug is safe and can he…

This study tests whether adding intravenous immunoglobulin (IVIG) to standard care helps people hospitalized with a sudden, severe worsening of idiopathic pulmonary fibrosis (IPF). About 196 adults with IPF who are having an acute exacerbation will receive either usual treatment …

This early-phase study tests a new drug called SV001 in 53 healthy Chinese adults to see if it is safe and how the body processes it. Participants receive a single dose of SV001 or a placebo. The goal is to check for side effects and measure drug levels in the blood. This is a fi…

This Phase 2 trial tests whether an oral drug called ifetroban can slow the decline in lung function for people with idiopathic pulmonary fibrosis (IPF), a progressive lung-scarring disease. About 128 adults aged 40 and older with IPF will receive either ifetroban or a placebo da…

This early-stage trial tests a single dose of an inhaled drug called RJ026 in 42 healthy volunteers and 42 people with interstitial lung disease (ILD). The goal is to see how much drug reaches the lungs and blood, and whether it is safe. Researchers hope that inhaling the drug wi…

This study is testing a new approach for people with severe lung disease (like pulmonary fibrosis or COPD) who also have bone marrow failure. First, participants receive a lung transplant to restore breathing. Then, about 8 weeks later, they get a bone marrow transplant using the…

This early-stage trial tests whether artesunate, a drug used for malaria, is safe for people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Fifteen adults with IPF will receive either artesunate capsules or a placebo for 12 week…

This study tests whether lansoprazole, a medicine that reduces stomach acid, can slow the progression of idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing problems. About 298 adults with IPF will take either lansoprazole or a placebo twice dai…

This study tests an experimental drug called SB17170 in 30 adults with moderate to severe idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Participants take either the drug or a placebo daily for 12 weeks. The main goal is to see if th…

This study is testing a new ultrasound measurement called the Lung Sliding Index (LSI) to see if it can help doctors tell apart different lung diseases, such as COPD, pneumonia, and pulmonary edema. Researchers will measure LSI in 700 adults with various lung conditions and healt…

This study tests a wearable device called the C-mo System that automatically detects and describes coughs. Researchers want to see if it can accurately count coughs, measure their intensity, and identify wheezing. 300 people aged 2 and older with cough-related conditions will wea…

This study tests whether a special PET scan (FAPI PET) can better detect active scarring in the lungs of people with fibrotic lung disease. About 50 adults with idiopathic pulmonary fibrosis or fibrotic hypersensitivity pneumonitis will get up to 4 PET/MRI scans. The goal is to i…

This early-phase study is testing a new imaging agent called [68Ga]CBP8 to see if it can safely and accurately detect collagen buildup (scarring) in the lungs. Researchers will compare scans from healthy volunteers, lung cancer patients, and people with pulmonary fibrosis. The go…

This study looks at whether automated software can consistently measure the amount of lung scarring (interstitial lung disease) on chest CT scans. Researchers will scan 150 adults with known lung scarring twice in a row to see if the measurements match. The goal is to improve the…

This study investigates whether drinking nitrate-rich beetroot juice twice a day for three days can improve exercise capacity in people with idiopathic pulmonary fibrosis (IPF), a lung scarring disease that limits activity. Researchers will compare the juice to a placebo in a sma…

This study tests whether using a portable oxygen concentrator (a lightweight, battery-powered device) during walking or exercise helps people with interstitial lung disease (ILD) or COPD feel less breathless and be more active in their daily lives. Twenty-four participants will t…

This study looks at whether drinking beetroot juice, which is high in nitrate, can help people with fibrotic interstitial lung disease exercise longer. Participants will drink either nitrate-rich or nitrate-free beetroot juice and then do a cycling test. The goal is to see if the…

This early-stage study is testing an extended-release tablet called nalbuphine ER in 10 people with idiopathic pulmonary fibrosis (IPF). The main goal is to see if the drug is safe and whether it affects breathing function. Researchers will monitor oxygen levels, breathing rate, …

This study tests whether a combination of zinc and nicotinamide riboside can help people with idiopathic pulmonary fibrosis (IPF) feel better and breathe easier. Sixty participants will take the supplements or a placebo twice a day for 24 weeks, all from home with remote check-in…

This study tests whether analyzing a patient's phlegm can help doctors choose better treatments for chronic cough in interstitial lung disease (ILD). About 120 adults with ILD and daily cough for at least 8 weeks will be randomly assigned to either phlegm-guided treatment or stan…

This study looks at whether an artificial intelligence (AI) tool can predict if lung scarring (pulmonary fibrosis) will get worse over time. Researchers will analyze CT scans from 200 people with either idiopathic pulmonary fibrosis (IPF) or other types of interstitial lung disea…

This study follows 4,000 people with interstitial lung disease (including conditions like pulmonary fibrosis and sarcoidosis) to understand how the disease naturally changes over time. Researchers will collect medical data and blood samples, and compare them to a healthy control …

This study tests whether two types of PET/CT scans can show inflammation and scarring in the lungs of people with idiopathic pulmonary fibrosis (IPF). Ten adults aged 40-85 with IPF will receive the scans. The goal is to help doctors better understand the disease and guide future…

This early-stage study tests how a new drug called ENV-101 (taladegib) interacts with two standard medicines for idiopathic pulmonary fibrosis (IPF): nintedanib and pirfenidone. About 57 healthy adults will take ENV-101 alone and with these drugs to measure how the body absorbs a…

This study looks at why people with interstitial lung disease (ILD) often feel breathless and have trouble exercising. Researchers think leg muscle problems might be a cause. They will measure leg muscle strength and structure in 40 ILD patients and test how extra oxygen affects …

This study looks at how pirfenidone changes the amount of a new medicine (BI 1015550) in the blood of adults with idiopathic pulmonary fibrosis (IPF). Twenty participants aged 40 and older will take both drugs over about a month. Researchers will measure blood levels to understan…

This study will use advanced MRI techniques to measure oxygen levels in the lungs of 50 people with early-stage idiopathic pulmonary fibrosis (IPF). The goal is to see if MRI can identify areas of low oxygen, which may be linked to disease progression. This is an observational st…

This study looks at 100 adults with fibrosing interstitial lung diseases (a type of lung scarring) to see if things like mold, dust, air pollution, and other home factors make the disease progress faster. Researchers will compare patients whose disease is getting worse to those w…

This study aims to develop a noninvasive way to detect blood vessel changes in the lungs of people with Group 3 pulmonary hypertension (PH) using a special MRI technique. Researchers will compare MRI results with lung tissue from 30 patients awaiting lung transplant. The goal is …

This Phase 1 trial tests the safety and tolerability of an investigational drug called SRN001 in 30 healthy Korean and Caucasian men. Participants receive either SRN001 or a placebo to see how the drug moves through the body and whether it causes side effects. The goal is to gath…

This study looks at whether the effort it takes to breathe can cause further lung damage in people with idiopathic pulmonary fibrosis (IPF). Researchers will measure breathing effort using a simple nose pressure test before and after exercise. The goal is to find patients whose b…

This study aims to understand how a gene called HOXB7 and related molecules behave in the lungs and blood of people with pulmonary fibrosis, a condition that causes lung scarring. Researchers will collect lung tissue and blood samples from 80 adults to look for biomarkers that mi…

This study uses a special type of MRI (called 129Xe gas exchange MRI) to take detailed pictures of how the lungs and heart work together. Researchers want to understand how these images change after treatments like blood transfusions or oxygen therapy. The study involves 125 adul…

This study looks at whether people newly diagnosed with idiopathic pulmonary fibrosis (IPF) have problems in their small airways, which are tiny air passages in the lungs. Researchers will use a simple breath test called nitrogen washout to check for these issues before starting …

This study follows 750 healthy family members of people with familial pulmonary fibrosis, a lung scarring disease that runs in families. Researchers will track participants with yearly questionnaires and in-person visits every two years to see who develops the disease and why. Th…

This study explores whether functional MRI can help doctors tell different types of interstitial lung disease apart and track how they change over time. About 200 adults with certain lung conditions will get MRI scans alongside standard CT scans. The goal is to see if MRI can pro…

This study aims to uncover the genetic causes of familial pulmonary fibrosis, a progressive lung disease that runs in families. Researchers will analyze DNA from 126 adults with a family history of the condition, looking for gene changes linked to lung scarring. The goal is to im…

This early-stage study tests a new medicine called GNS-3545 in 72 healthy adults to see if it is safe and how the body processes it. The drug is being developed for idiopathic pulmonary fibrosis, a disease that causes lung scarring. Participants will receive either the drug or a …

This study collects blood samples from 2,000 adults with pulmonary fibrosis to find genetic traits that may explain why they developed the disease and why scarring patterns differ. Participants must be 18 or older and have a confirmed diagnosis. The goal is to better understand t…

This study is collecting blood and tissue samples from 500 people with idiopathic pulmonary fibrosis to find genetic and protein markers that might predict rapid lung function decline. Researchers will compare these markers with changes in symptoms over time. The goal is to bette…

This study is creating a registry and biobank for people with interstitial lung diseases (ILD), including sarcoidosis, idiopathic pulmonary fibrosis, and hypersensitivity pneumonitis. Researchers will collect medical data and biological samples from up to 1,000 participants to su…